2024 ASCO | Relma-cel Achieves a 4-Year OS Rate of 66.7% in Treating R/R LBCL, Making Lymphoma Cure Possible

2024 ASCO | Relma-cel Achieves a 4-Year OS Rate of 66.7% in Treating R/R LBCL, Making Lymphoma Cure Possible

Lymphoma

Over the past few decades, there have been significant advancements in the treatment of hematologic malignancies, particularly with CAR-T cell therapy. Recently, Relma-cel (relmacabtagene autoleucel) showcased promising new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its remarkable efficacy in treating relapsed/refractory large B-cell lymphoma (R/R LBCL).

### Breakthrough in CAR-T Therapy

Relma-cel is a CD19-targeted CAR-T cell therapy that reprograms a patient’s own T cells to recognize and attack cancer cells. Studies have shown that Relma-cel achieves a 4-year overall survival (OS) rate of 66.7% in patients with R/R LBCL, with the rate soaring to 82.5% for those who achieve complete remission (CR). These results indicate that Relma-cel not only significantly extends survival but also increases the cure rate for these patients.

### The Power of Long-Term Follow-Up Data

The RELIANCE study, one of the largest CAR-T cell therapy studies in China, aims to evaluate the efficacy and safety of Relma-cel in R/R LBCL patients. The latest 4-year follow-up data reveals that 25 patients remain alive, and the median overall survival (OS) has not yet been reached. This milestone offers immense hope for patients and physicians, underscoring the long-term survival benefits of this therapy.

### Balancing Safety and Efficacy

Relma-cel also excels in safety. The incidence rates of ≥3 grade cytokine release syndrome (CRS) and neurotoxicity (NT) are 5.1% and 3.4%, respectively. Compared to other CD19 CAR-T cell therapies, Relma-cel effectively reduces side effects while significantly enhancing efficacy. This success is largely attributed to its unique CAR structure design, which includes a 4-1BB costimulatory domain, a CD28 transmembrane domain, and an optimized hinge region. These features enable Relma-cel to survive longer in the body and enhance its tumor-killing power.

### Future Prospects

As Relma-cel continues to expand its reach, more R/R LBCL patients are expected to benefit from this advanced treatment. Currently, Relma-cel is exploring its potential use in second-line treatment for LBCL and frontline therapy for high-risk LBCL patients. Additionally, it has shown excellent clinical value in treating relapsed/refractory follicular lymphoma (R/R FL) and mantle cell lymphoma (R/R MCL).

Relma-cel’s success not only brings new hope to lymphoma patients but also signifies a new era in the treatment of hematologic malignancies. We look forward to more research findings on Relma-cel, which will bring hope and possibilities for curing lymphoma to patients worldwide.

With Relma-cel, curing lymphoma is no longer an unattainable dream. Let’s anticipate more breakthroughs in this field, bringing new light to the lives of every patient.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#LymphomaTreatment #CAR_TTherapy #CancerResearch #RelmaCel #HopeForPatients #MedicalAdvancements #ASCO2024 #InnovativeTherapies #Survivorship #CureLymphoma

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

5 months ago Solid tumor

2024 ASCO China Highlights: China’s Indigenous TIL Therapy – GT101: Targeting Multiple Solid Tumors with a 90.9% Disease Control Rate

**2024 ASCO China Highlights: China’s Indigenous TIL Therapy Makes a Strong Debut, Targeting Small Cell Lung Cancer, Melanoma, Cervical Cancer, with a DCR Over 90%**

**GT101: Targeting Multiple Solid Tumors with a 90.9% Disease Control Rate**

TIL Therapy

GT101, independently developed by Gravel Biotech, is an autologous tumor-infiltrating lymphocyte (TIL) therapy. On April 22, 2022, its clinical trial implied consent was approved by the National Medical Products Administration (NMPA) (Acceptance No.: CXSL2200061). It is indicated for treating various solid tumors including non-small cell lung cancer, melanoma, and cervical cancer. Notably, GT101 is China’s first approved clinical TIL cell therapy and holds promise as the first cell therapy to conquer solid tumors!

Recently, at the 2024 ASCO Annual Meeting, results from the Phase 1 clinical trial of GT101 TIL therapy (NCT05430373) were announced. By November 10, 2023, a total of 14 patients with recurrent or metastatic solid tumors (including small cell lung cancer, melanoma, cervical cancer) had been enrolled, all with an ECOG performance status of 0 or 1 and having received a median of 2.6 prior lines of therapy. After enrollment, tumor tissue was obtained via appropriate surgical procedures for GT101 preparation, followed by approximately 30 days of TIL cell culture. Patients then underwent non-myeloablative lymphocyte depletion (cyclophosphamide + fludarabine), GT101 reinfusion therapy, and IL-2 (Interleukin-2) treatment.

1. **All enrolled patients (n=14):** The Objective Response Rate (ORR) was 35.7%. Among them, 28.6% (4 patients) achieved partial response (PR), 57.1% (8 patients) achieved stable disease (SD), and 7.1% (1 patient) achieved complete response (CR).

2. **In cervical cancer patients (n=11):** The Objective Response Rate (ORR) reached 45.5% (5/11). The Disease Control Rate (DCR) was as high as 90.9% (10/11), with 36.4% (4 patients) achieving partial response (PR) and 9.1% (1 patient) achieving complete response (CR). The median Progression-Free Survival (PFS) was 4.2 months. According to Kaplan-Meier statistics, the durations of complete response (CR) and progression-free survival (PFS) were 24 weeks and 36 weeks, respectively.

In conclusion, GT101 demonstrated promising clinical efficacy and manageable safety in combination with lymphocyte depletion and high-dose IL-2 treatment. Particularly in the treatment of cervical cancer, its objective response rate and duration of response are remarkable!

**How to Seek Help from TIL Therapy?**

The good news is that several TIL therapy clinical trials are currently recruiting in China, primarily targeting various solid tumors such as non-small cell lung cancer, melanoma, cholangiocarcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, fallopian tube cancer, urothelial cancer, and renal cancer.

Patients seeking help from TIL therapy can submit their complete treatment history, recent pathology reports, imaging examination reports, and discharge summaries to Advanced Medicine in China

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#ASCO2024 #TILTherapy #GT101 #CancerResearch #SolidTumors #ClinicalTrials #LungCancer #Melanoma #CervicalCancer #Immunotherapy #ChinaBiotech #CancerTreatment